Science news and discussion on TalkFuse.
Alzheimer’s blood marker could predict cognitive decline risks, Mayo Clinic says
A Mayo Clinic study suggests that measuring the Alzheimer’s-linked blood protein p-tau217, alongside a person’s age, could help estimate the chance of cognitive decline over the next five to 10 years. The findings may support more personalised risk discussions if preventive treatments become available, but the researchers say the test is not ready for routine screening.
The study followed 2,178 adults aged 60 to 90 who had no cognitive impairment at the outset. At the same elevated p-tau217 level, the estimated five-year risk of mild cognitive impairment was 6% for a 65-year-old and 37% for an 85-year-old; the APOE ε4 variant had a more modest association with risk. The model was developed using participants from south-east Minnesota and needs validation in other populations; no approved treatment currently makes testing useful for people without symptoms.
In short
- Blood p-tau217 may help estimate future cognitive decline risk.
- Age strongly affected the estimates in the study.
- Researchers say the test is not ready for routine screening.